Mark Ragosa - 01 Sep 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
01 Sep 2022
Net transactions value
-$6,258
Form type
4
Filing time
06 Sep 2022, 16:10:03 UTC
Previous filing
28 Apr 2022
Next filing
20 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +1,861 +29% 8,218 02 Sep 2022 Direct F1
transaction KNSA Class A Common Share Tax liability $6,258 -547 -6.7% $11.44 7,671 02 Sep 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Award $0 +64,660 $0.000000 64,660 01 Sep 2022 Class A Common Share 64,660 $11.97 Direct F2
transaction KNSA Restricted Share Unit Award $0 +10,777 $0.000000 10,777 01 Sep 2022 Class A Common Share 10,777 Direct F1, F3
transaction KNSA Restricted Share Unit Options Exercise $0 -1,861 -25% $0.000000 5,583 02 Sep 2022 Class A Common Share 1,861 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.
F3 The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
F4 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.